HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bosentan (Tracleer)

endothelin receptor antagonist

Also Known As:

Tracleer; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; Actelion brand of bosentan monohydrate; Ro 47-0203; Ro-47-0203; bosentan monohydrate

Networked: 820 relevant articles (150 outcomes, 185 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Amides: 231
  - Sulfonamides: 931
    - bosentan: 820
- Sulfur Compounds: 135
  - Sulfones: 136
    - Sulfonamides: 931
      - bosentan: 820

Experts

1.	Clozel, Martine: 9 articles (11/2015 - 03/2002)
2.	Dingemanse, Jasper: 8 articles (03/2015 - 04/2002)
3.	Simonneau, Gérald: 8 articles (01/2013 - 12/2004)
4.	Humbert, Marc: 8 articles (01/2013 - 12/2004)
5.	Naeije, Robert: 8 articles (09/2010 - 03/2003)
6.	Prous, J R: 8 articles (09/2006 - 06/2004)
7.	Berger, Rolf M F: 7 articles (02/2014 - 07/2006)
8.	Sitbon, Olivier: 7 articles (01/2013 - 12/2004)
9.	Humbert, M: 7 articles (07/2010 - 01/2003)
10.	Rabasseda, X: 7 articles (09/2006 - 06/2004)

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 08/01/2011 - "Bosentan has proven efficacy in pulmonary hypertension in the short term. " 12/01/2006 - "The results of this study suggest that treatment with bosentan is associated with long-term improvement in clinical variables and exercise capacity in approximately two thirds of the patients with pulmonary hypertension." 03/01/2013 - "Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device." 09/01/2009 - "Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension." 05/01/2009 - "Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension."
2.	Ulcer 01/01/2012 - "These results suggest that bosentan is an effective treatment for refractory digital ulcers associated with SSc; however, liver function should be carefully monitored. " 01/01/2013 - "The reduction of ET-1 levels in DUs patients in therapy with bosentan confirms the efficacy of this molecule both for treatment and prevention of digital ulcers. " 01/01/2013 - "A few recent observations showed the efficacy of bosentan for accelerating the healing of nondigital ulcers in scleroderma patients. " 02/01/2012 - "The efficacy of bosentan on nondigital ulcers and its association with clinical features of ulcers were analysed. " 02/01/2012 - "To evaluate the efficacy of bosentan on nondigital ulcers in patients with SSc. "
3.	Systemic Scleroderma (Systemic Sclerosis) 04/01/2015 - "We present a challenging case of PAH in a patient with systemic sclerosis in whom a marked decrease in functional capacity after the initiation of bosentan therapy led to the diagnosis of PVOD. " 10/01/2011 - "Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis." 07/01/2015 - "Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study." 12/01/2006 - "Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study." 07/01/2015 - "In systemic sclerosis (SSc), clinical evidence has shown that Bosentan may foster the regeneration of the peripheral microcirculatory network. "
4.	Eisenmenger Complex (Eisenmenger's Syndrome) 05/01/2010 - "In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmonary blood flow, and PVR. " 05/01/2006 - "This study showed a clear functional improvement in patients with Eisenmenger's syndrome treated with bosentan. " 05/29/2009 - "In this open-label study, 24 Down patients (>18 years) with Eisenmenger syndrome (17 males) were treated with bosentan. " 05/29/2009 - "In this study, we evaluate the therapeutic role of bosentan treatment in Down patients with Eisenmenger syndrome. " 06/23/2008 - "Following the 16-week, double blind, placebo-controlled BREATHE-5 study of bosentan in patients with Eisenmenger syndrome, an open-label extension (OLE) was performed. "
5.	Heart Diseases (Heart Disease) 11/15/2011 - "The aim of this study was to retrospectively analyze the long-term efficacy and safety of bosentan in adults with PAH secondary to congenital heart disease (PAH-CHD). " 11/01/2006 - "However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD). " 07/01/2012 - "Bosentan is the only medication to date to be compared with placebo in a randomized controlled trial specifically targeting congenital heart disease-associated PAH. " 05/01/2007 - "To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). " 09/01/2006 - "Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD). "

Related Drugs and Biologics

1.	Endothelin Receptors (Endothelin Receptor)
2.	Idiopathic pulmonary hypertension
3.	sildenafil (Viagra)
4.	Endothelins (Endothelin)
5.	Endothelin-1 (Endothelin 1)
6.	Oxygen
7.	Endothelin A Receptor
8.	Iloprost (Ventavis)
9.	Epoprostenol (Prostacyclin)
10.	cyclo(Trp-Asp-Pro-Val-Leu)

Related Therapies and Procedures

1.	Oral Administration
2.	Renal Dialysis (Hemodialysis)
3.	Transplants (Transplant)
4.	Heart Transplantation (Grafting, Heart)
5.	Stents